# Selinexor (Xpovio)

Source: https://ourhealthnetwork.com/drugs/selinexor
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Selinexor?

Selinexor (brand name: Xpovio) is a nuclear export inhibitor. It is prescribed to treat multiple myeloma. Across the United States, 43 doctors prescribe Selinexor to approximately 26 Medicare patients.

## Brand names

Xpovio

## Indications

Selinexor is primarily prescribed for the treatment of multiple myeloma.

## Conditions treated

- [Multiple Myeloma](https://ourhealthnetwork.com/conditions/multiple-myeloma)

## Mechanism of action

In nonclinical studies, selinexor reversibly inhibits nuclear export of tumor suppressor proteins (TSPs), growth regulators, and mRNAs of oncogenic proteins by blocking exportin 1 (XPO1). XPO1 inhibition by selinexor leads to accumulation of TSPs in the nucleus and reductions in several oncoproteins, such as c-myc and cyclin D1, cell cycle arrest, and apoptosis of cancer cells.

## Drug classification

- Established Pharmacologic Class: Nuclear Export Inhibitor [EPC]
- Mechanism of Action class: Nuclear Export Inhibitors [MoA]
- Route of administration: ORAL

## Common side effects

of patients included pneumonia

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)